Maryland, USA-based vaccine specialist Novavax (Nasdaq: NVAX) is to commence Phase III trials of its novel coronavirus vaccine candidate in children aged 12 to 17.
In a sign of the firm’s confidence in the product, the program comes ahead of any regulatory approvals having been secured for NVX-CoV2373, a vaccine which uses a traditional recombinant protein-based approach.
In January, the company released positive Phase III data which showed vaccine efficacy of 89.3% in trials conducted in the UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze